Taro Pharma's sales declined 33% QoQ to US$118m in Q1FY21 v/s US$175m in Q4FY20. The company reported lowest revenue in last 36 quarters including lowest ever gross profit and gross margin. Though Q4FY20 was an exceptional quarter where revenues shot up due to stocking up during COVID yet its revenue, gross profit and gross margin continued to be impacted due to derma products price erosion. Taro reported net loss of US$434m due to...